Fenofibrate
Non Familial Chylocmicronemia Syndrome (Non-FCS)
Novartis PharmaceuticalsSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Non Familial Chylocmicronemia Syndrome (Non-FCS) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Volanesorsen Akcea Therapeutics | Phase 3 | B |
VUPANORSEN Akcea Therapeutics | Phase 2 | B |
lcq908 Novartis Pharmaceuticals | Phase 2 | B |
Same molecule, other indications
Fenofibrate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →